儿童急性淋巴细胞白血病合并血栓栓塞研究进展

doi:10.12372/jcp.2022.22e0158

摘要/Abstract

摘要：

急性淋巴细胞白血病（ALL）是儿童最常见的恶性血液系统疾病,也是最常见的合并血栓的恶性肿瘤。血栓栓塞和患儿凝血功能异常与化疗药物、感染、深静脉置管以及遗传因素等有关,严重者可危及生命。文章就ALL患儿血栓栓塞的发生机制、临床特点、危险因素及治疗进展进行综述,以提高对儿童ALL合并血栓栓塞的认识。

关键词: 急性淋巴细胞白血病, 凝血功能, 血栓栓塞, 儿童

Abstract:

Acute lymphoblastic leukemia (ALL) is the commonest hematological malignancy in children, and also the commonest malignant tumor associated with thrombosis. Thromboembolism and abnormal coagulation function in children are related to chemotherapy drugs, infection, deep vein catheterization and genetic factors, and can endanger life in severe cases. This article reviewed the pathogenesis, clinical characteristics, risk factors and treatment progress of thromboembolism in children with ALL, in order to improve the understanding of thromboembolism in children with ALL.

Key words: acute lymphoblastic leukemia, coagulant function, thromboembolism, childrer

李贝多, 邵静波. 儿童急性淋巴细胞白血病合并血栓栓塞研究进展[J]. 临床儿科杂志, 2022, 40(6): 475-480.

LI Beiduo, SHAO Jingbo. The research progress of acute lymphoblastic leukemia with thromboembolism in children[J]. Journal of Clinical Pediatrics, 2022, 40(6): 475-480.

参考文献 33

[1]	Athale UH, Laverdiere C, Nayiager T, et al. Evaluation for inherited and acquired prothrombotic defects predisposing to symptomatic thromboembolism in children with acute lymphoblastic leukemia: a protocol for a prospective, observational, cohort study[J]. BMC Cancer, 2017, 17(1): 313. doi: 10.1186/s12885-017-3306-5 pmid: 28472942
[2]	O'Brien SH, Li D, Mitchell LG, et al. PREVAPIX-ALL: apixaban compared to standard of care for prevention of venous thrombosis in paediatric acute lymphoblastic leukaemia (all)-rationale and design[J]. Thromb Haemost, 2019, 119(5): 844-853. doi: 10.1055/s-0039-1679938
[3]	Zara M, Guidetti GF, Camera M, et al. Biology and role of extracellular vesicles (EVs) in the pathogenesis of thrombosis[J]. Int J Mol Sci, 2019, 20(11): 2840. doi: 10.3390/ijms20112840
[4]	Mitchell LG, Halton JM, Vegh PA, et al. Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia[J]. Am J Pediatr Hematol Oncol, 1994, 16(2): 120-126.
[5]	Ramacciotti E, Hawley AE, Wrobleski SK, et al. Proteomics of microparticles after deep venous thrombosis[J]. Thromb Res, 2010, 125(6): e269-e274.
[6]	Mateos MK, Trahair TN, Mayoh C, et al. Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia[J]. Thromb Res, 2019, 178: 132-138. doi: S0049-3848(19)30194-X pmid: 31030032
[7]	罗学群. 不同类型左旋门冬酰胺酶的特点及临床应用[J]. 中国小儿血液与肿瘤杂志, 2013, 18(1).
[8]	Kashanian SM, Holtzman NG, Patzke CL, et al. Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens[J]. Cancer Chemother Pharmacol, 2021, 87(6): 817-826. doi: 10.1007/s00280-021-04252-y
[9]	Debbie Jiang MD, Alfred Ian Lee MD. Thrombotic risk from chemotherapy and other cancer therapies[J]. Cancer Treat Res, 2019, 179: 87-101. doi: 10.1007/978-3-030-20315-3_6 pmid: 31317482
[10]	Truelove E, Fielding AK, Hunt BJ. The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia[J]. Leukemia, 2013, 27(3): 553-559. doi: 10.1038/leu.2012.290 pmid: 23099335
[11]	黄倩云, 李长钢. 门冬酰胺酶对白血病患儿静脉血栓形成的研究进展[J]. 医学信息, 2018, 31(12).
[12]	王西阁, 郭怡丹, 赵雪莲, 等. 培门冬酶与门冬酰胺酶对儿童急性淋巴细胞白血病诱导缓解治疗中凝血功能的影响[J]. 实用医药杂志, 2018, 35(1): 18-20.
[13]	Ruiz-Llobet A, Gassiot S, Sarrate E, et al. Venous thromboembolism in pediatric patients with acute lymphoblastic leukemia under chemotherapy treatment. Risk factors and usefulness of thromboprophylaxis. Results of LAL-SEHOP-PETHEMA-2013[J]. J Thromb Haemost, 2022. doi: 10.1111/jth.15699. doi: 10.1111/jth.15699
[14]	Koch A, Meesters MI, Scheller B, et al. Systemic endotoxin activity correlates with clot formation: an observational study in patients with early systemic inflammation and sepsis[J]. Crit Care, 2013, 17(5): R198. doi: 10.1186/cc12892
[15]	Li T, Peng R, Wang F, et al. Lysophosphatidic acid promotes thrombus stability by inducing rapid formation of neutrophil extracellular traps: a new mechanism of thrombosis[J]. J Thromb Haemost, 2020, 18(8): 1952-1964. doi: 10.1111/jth.14839
[16]	Fang Y, Garnier D, Lee TH, et al. PML-RARa modulates the vascular signature of extracellular vesicles released by acute promyelocytic leukemia cells[J]. Angiogenesis, 2016, 19(1): 25-38. doi: 10.1007/s10456-015-9486-1 pmid: 26374632
[17]	Monagle P, Chalmers E, Chan A, et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)[J]. Chest, 2008, 133(6 Suppl): 887S-968S. doi: 10.1378/chest.08-0762 pmid: 18574281
[18]	Ren Y, Chang L, Zhao B, et al. Venous thromboembolism after peripherally inserted central catheters placement in children with acute leukemia: a single-center retrospective cohort study[J]. J Pediat Hematol Oncol, 2020, 42(6): e407-e409.
[19]	王水英, 熊辉霞. 急性白血病合并易栓症的研究进展[J]. Chinese Journal of Thrombosis and Hemostasis, 2017, 23(1).
[20]	马青变, 郑亚安, 朱继红, 等. 中国急性血栓性疾病抗栓治疗共识[J]. 中国急救医学, 2019, 39(6).
[21]	Jarvis KB, Andersson NG, Giertz M, et al. Asymptomatic right atrial thrombosis after acute lymphoblastic leukemia treatment[J]. J Pediatr Hematol Oncol, 2021, 43(4): e564-e566.
[22]	刘卫娟, 叶绿苗, 王瑛, 等. B超随访与肿瘤患者PICC导管相关性血栓检出的相关性研究[J]. 中国医疗前沿, 2013, 8(19).
[23]	Malhotra P, Jain S, Kapoor G. Symptomatic cerebral sinovenous thrombosis associated with L-asparaginase in children with acute lymphoblastic leukemia: a single institution experience over 17 years[J]. J Pediatr Hematol Oncol, 2018, 40(7): e450-e453.
[24]	Korones DN, Buzzard CJ, Asselin BL, et al. Right atrial thrombi in children with cancer and indwelling catheters[J]. J Pediatr, 1996, 128(6): 841-846. doi: 10.1016/S0022-3476(96)70338-4
[25]	Mitchell LG, Andrew M, Hanna K, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study[J]. Cancer, 2003, 97(2): 508-516. pmid: 12518376
[26]	Sawaya RD, Cheaito R, Cheaito MA, et al. Pulmonary embolism can be nauseous: a case report and review of D-dimer use in pediatric oncology patients[J]. J Emerg Med, 2020, 58(6): 927-931. doi: S0736-4679(19)31118-7 pmid: 32001119
[27]	Qdaisat A, Soud RA, Wu CC, et al. Poor performance of D-dimer in excluding venous thromboembolism among patients with lymphoma and leukemia[J]. Haematologica, 2019, 104(6): e265-e268.
[28]	Greiner J, Schrappe M, Claviez A, et al. THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents[J]. Haematologica, 2019, 104(4): 756-765. doi: 10.3324/haematol.2018.194175
[29]	Hashem H, Zeineddin M, Bater R, et al. Thrombosis and anticoagulant therapy among pediatric cancer patients: real-life data[J]. Cureus, 2021, 13(12): e20084.
[30]	Barg AA, Kenet G. Cancer-associated thrombosis in pediatric patients[J]. Thromb Res, 2020, 191(Suppl 1): S22-S25.
[31]	Degliuomini M, Cooley V, Mauer E, et al. Assessment of provider practices regarding venous thromboembolism management and prevention in pediatric acute leukemia patients[J]. J Thromb Thrombolysis, 2021, 52(1): 209-213. doi: 10.1007/s11239-021-02379-6
[32]	Sorigue M, Cañamero E, Siguenza P, et al. Recent developments and persisting challenges in the prevention and treatment of venous thromboembolism in patients with hematological malignancies[J]. Leuk Lymphoma, 2020, 61(6): 1277-1291. doi: 10.1080/10428194.2020.1713321
[33]	Young G, Lensing AWA, Monagle P, et al. Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation[J]. J Thromb Haemost, 2020, 18(7): 1672-1685. doi: 10.1111/jth.14813 pmid: 32246743